Ocular Therapeut (OCUL) Stock Price, Quote & News

Company Profile

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that i...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 357 4000

Website: www.ocutx.com

Address:

15 Crosby Drive, Bedford, United States

skoobastev3 Mar. 16 at 12:13 AM

$OCUL lets gooo get your dca down

0 · Reply

WarrenDouglasTrader Mar. 15 at 4:39 PM

$OCUL Cmon buyout! Sanofi where are you?

0 · Reply

MaxKlim Mar. 13 at 9:12 PM

$OCUL https://x.com/ocutx/status/2031729389067506098?s=46

0 · Reply

DiddyK0ng Mar. 13 at 5:59 PM

$OCUL According to my analytical skills, the stock will rise again.

3 · Reply

Jjarnold44 Mar. 13 at 5:21 PM

$OCUL Just a matter of time. This WILL get an approved NDA with superiority and it WILL fly. Until then, ignore the noise. Not ONE of these idiots has offered ANY analysis worth a single cent.

4 · Reply

DiddyK0ng Mar. 13 at 3:50 PM

$OCUL maydaymayday

0 · Reply

_MarginOfSanity_ Mar. 13 at 3:44 PM

$OCUL triggered stop loss. Shakedown. Bio Pharma is very manipulated. Will wait till they take it lower. Will re enter <$8. No major catalyst until NDA filing. Ultimately this will be going to $20+ within a year.

0 · Reply

Thundr1 Mar. 13 at 3:34 PM

$OCUL Added another 1500. This will be volatile until FDA discussions about the NDA filing path, and or confirmation the company will submit the NDA. Keep your eye on the prize!

1 · Reply

Tmoney85285 Mar. 13 at 3:15 PM

$OCUL keep blaming macros, but the truth is these losses FAR outpace anything going on in XBI. Gee I wonder why?!!

0 · Reply

momos Mar. 13 at 3:05 PM

$OCUL lower highs, lower lows. Back to being dead money for foreseeable future. Wake me up in 6 months…

1 · Reply

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 2, 2026, 4:37 PM EST - 13 days ago

Ocular Therapeutix, Inc. (OCUL) Discusses Phase III SOL-1 Data Highlighting Transformative Durability in Wet AMD Transcript

Feb 19, 2026, 10:41 AM EST - 24 days ago

Ocular Therapeutix Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Feb 17, 2026, 4:15 PM EST - 26 days ago

Ocular Therapeutix, Inc. (OCUL) Discusses Positive Top Line Results From SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD Transcript

Feb 17, 2026, 7:08 AM EST - 26 days ago

Ocular Therapeutix's eye drug superior to Regeneron's Eylea in late-stage trial

REGN

Feb 13, 2026, 5:00 PM EST - 4 weeks ago

Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026

Feb 6, 2026, 4:01 PM EST - 5 weeks ago

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 4, 2026, 7:30 AM EST - 5 weeks ago

Ocular Therapeutix: Why SOL-1 Trial Outcome Is Likely Positive

Dec 8, 2025, 12:59 PM EST - 3 months ago

Ocular Therapeutix Stock Skyrockets On Faster FDA Path For Vision Drug

Nov 4, 2025, 3:16 PM EST - 4 months ago

Ocular Therapeutix, Inc. (OCUL) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 7:05 AM EST - 4 months ago

Ocular Therapeutix™ Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 4, 2025, 7:00 AM EST - 4 months ago

Ocular Therapeutix™ Achieves Target Randomization of 555 Subjects in SOL-R

Oct 7, 2025, 7:00 AM EDT - 5 months ago

Ocular Therapeutix™ to Participate in Upcoming Scientific Conferences

Oct 1, 2025, 4:22 AM EDT - 5 months ago

Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day Transcript

Sep 30, 2025, 7:08 AM EDT - 5 months ago

Ocular Therapeutix™ Announces Pricing of Underwritten Offering of Common Stock

Sep 30, 2025, 6:21 AM EDT - 5 months ago

Ocular Therapeutix™ Investor Day to Highlight Exceptional AXPAXLI™ Progress Across SOL Program and Detail Registrational Trial Plans to Pursue a Diabetic Retinopathy Label with a Novel Primary Endpoint

Sep 8, 2025, 5:05 PM EDT - 6 months ago

Ocular Therapeutix, Inc. (OCUL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 7, 2025, 1:52 AM EDT - 6 months ago

Ocular Therapeutix: A High-Stakes Bet On Becoming The New Standard Of Care

Aug 5, 2025, 1:33 PM EDT - 7 months ago

Ocular Therapeutix, Inc. (OCUL) Q2 2025 Earnings Call Transcript

Jun 26, 2025, 1:54 PM EDT - 9 months ago

Ocular Therapeutix™ Unveils New Corporate Branding, Reflecting its Transformation to a Retina-Focused Company

Jun 16, 2025, 7:00 AM EDT - 9 months ago

Ocular Therapeutix™ to Participate in Clinical Trials at the Summit (CTS) 2025

May 14, 2025, 7:00 AM EDT - 10 months ago

Ocular Therapeutix™ to Participate in Upcoming Investor Conferences

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Ocular Therapeutix™ to Participate in Two Investor Conferences in April

Mar 11, 2025, 2:49 PM EDT - 1 year ago

Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside

Mar 6, 2025, 11:15 AM EST - 1 year ago

Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster Potential

Mar 3, 2025, 10:16 AM EST - 1 year ago

Ocular Therapeutix, Inc. (OCUL) Q4 2024 Earnings Call Transcript

Feb 24, 2025, 7:00 AM EST - 1 year ago

Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

Feb 3, 2025, 7:00 AM EST - 1 year ago

Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting

Jan 14, 2025, 7:00 AM EST - 1 year ago

Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR

Dec 30, 2024, 12:16 PM EST - 1 year ago

Ocular Is Now Thoroughly Derisked

Dec 10, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 2, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1

Nov 26, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences

Nov 14, 2024, 10:34 AM EST - 1 year ago

Ocular Therapeutix, Inc. (OCUL) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV

Nov 6, 2024, 7:30 AM EST - 1 year ago

Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024

Oct 15, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD

Oct 11, 2024, 5:50 AM EDT - 1 year ago

Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors

AMD

Oct 9, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at October Ophthalmology Meetings

Sep 25, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024

Sep 5, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at September Retina Meetings

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Present at Two Investor Conferences in September

Aug 9, 2024, 12:53 PM EDT - 1 year ago

Ocular Therapeutix, Inc. (OCUL) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 7:10 AM EDT - 1 year ago

Ocular Therapeutix™ Reports Second Quarter 2024 Results

Jul 31, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024

Jul 30, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study

Jul 10, 2024, 8:00 AM EDT - 1 year ago

Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting

Jun 20, 2024, 9:13 AM EDT - 1 year ago

This Skyworks Solutions Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

SWKS BFH IRTC TRU

Jun 13, 2024, 4:05 PM EDT - 1 year ago

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study

Jun 5, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix® to Host Investor Day on June 13, 2024

skoobastev3 Mar. 16 at 12:13 AM

$OCUL lets gooo get your dca down

0 · Reply

WarrenDouglasTrader Mar. 15 at 4:39 PM

$OCUL Cmon buyout! Sanofi where are you?

0 · Reply

MaxKlim Mar. 13 at 9:12 PM

$OCUL https://x.com/ocutx/status/2031729389067506098?s=46

0 · Reply

DiddyK0ng Mar. 13 at 5:59 PM

$OCUL According to my analytical skills, the stock will rise again.

3 · Reply

Jjarnold44 Mar. 13 at 5:21 PM

$OCUL Just a matter of time. This WILL get an approved NDA with superiority and it WILL fly. Until then, ignore the noise. Not ONE of these idiots has offered ANY analysis worth a single cent.

4 · Reply

DiddyK0ng Mar. 13 at 3:50 PM

$OCUL maydaymayday

0 · Reply

_MarginOfSanity_ Mar. 13 at 3:44 PM

0 · Reply

Thundr1 Mar. 13 at 3:34 PM

$OCUL Added another 1500. This will be volatile until FDA discussions about the NDA filing path, and or confirmation the company will submit the NDA. Keep your eye on the prize!

1 · Reply

Tmoney85285 Mar. 13 at 3:15 PM

$OCUL keep blaming macros, but the truth is these losses FAR outpace anything going on in XBI. Gee I wonder why?!!

0 · Reply

momos Mar. 13 at 3:05 PM

$OCUL lower highs, lower lows. Back to being dead money for foreseeable future. Wake me up in 6 months…

1 · Reply

Sarge986 Mar. 13 at 2:56 PM

. Ocular Therapeutix Gets Black Eye, But I See Stock Rising on New Drug $OCUL #StocksUnder10 #SU10 #MarketRecon #SmallCaps .. https://pro.thestreet.com/trade-ideas/ocular-therapeutix-gets-black-eye-but-i-see-stock-rising-on-new-drug

0 · Reply

Tmoney85285 Mar. 13 at 2:43 PM

$OCUL another day, another walloping for TKI stocks. Fact- these stocks are going to get much much worse before they get any better, if they do get better, at all. Q1 tute holding numbers will be ugly- you heard it here first!

0 · Reply

WarrenDouglasTrader Mar. 13 at 2:17 PM

$OCUL Technically broken now. Not good.

1 · Reply

Dontknowwhatimdoing95 Mar. 13 at 2:06 PM

$OCUL me rn

0 · Reply

WarrenDouglasTrader Mar. 13 at 1:56 PM

$OCUL Where is Sanofi?

0 · Reply

Im_Naruto Mar. 13 at 1:52 PM

Just FYI $CAPR $OCUL $OCGN all of these have 100% buy rating.. and all of them are outperforming…

0 · Reply

Glenderblender Mar. 13 at 8:23 AM

$OCUL Ocul Thera... Ocult?

0 · Reply

rizzato Mar. 13 at 2:25 AM

$OCUL Tmoney you continue to say big institution are selling without having any prove of that , as always if you have something please let us know if not please stop to speak for nothing and note that the numbers of the shares sold are not showing an escape from the company and the main share holders are not selling at all

2 · Reply

acdurham Mar. 12 at 10:30 PM

$OCUL if I had a NDA application ready and prepared and FDA guidance to submit…I would not release or announce that in this dismal Trump-inspired war market. Just sit on it.

2 · Reply

Nosh Mar. 12 at 7:57 PM

$OCUL Starter here....

2 · Reply

_MarginOfSanity_ Mar. 12 at 4:18 PM

$OCUL buyout is a double edged sword for investors. If there are multiple buyout offers on the table, the acquirers can work with hedge funds and market makers to collapse the stock price, forcing management to accept a lower offer than why the investors deserve. This also discourages investors and forces them to sell. Once the buyout price is agreed upon and until it is announced, hedge funds will use the artificially lowered stock price as entry point, netting themselves a phantom premium

2 · Reply

_MarginOfSanity_ Mar. 12 at 3:39 PM

$OCUL 👇and child trafficking. Why would Epstein buy gallons of sulfuric acid after he was indicted?

0 · Reply

Market Cap	1.91B
Revenue (ttm)	51.95M
Net Income (ttm)	-265.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-511.92%
Debt to Equity Ratio	0.11

Volume	3,725,200
Avg Vol	6,890,446
Day's Range	N/A - N/A
Shares Out	217.69M
Stochastic %K	9%
Beta	0.91
Analysts	Strong Sell
Price Target	$24.85